IDH2 and leukemia: Ivosidenib and enasidenib specifically inhibit the activity of mutated IDH1 and IDH2 enzymes respectively to lower the 2-HG levels, which helps to restore the differentiation process of cells and reduces the malignant proliferation of leukemia cells.